ASCO 2015 Highlights

Characteristics of Patients with Mantle-Cell Lymphoma and Chronic Lymphocytic Leukemia Treated with Acalabrutinib in a US Real-World Setting
ASH 2019 Wrap-up
Conference Correspondent
Insights about real-world clinical experience with new drugs, such as acalabrutinib, are highly valuable. At ASH 2019, researchers evaluated acalabrutinib use in real-world patients with mantle-cell lymphoma and chronic lymphocytic leukemia.
Read Article
Phase 3 Trial Compares Acalabrutinib plus Venetoclax with or without Obinutuzumab versus Chemoimmunotherapy as First-Line Therapy in Patients with Chronic Lymphocytic Leukemia and No del(17p) or TP53 Mutations
ASH 2019 Wrap-up
Conference Correspondent
Current treatments for chronic lymphocytic leukemia are limited by cost, toxicity, and duration of response. In the future, less toxic first-line chemotherapy-free regimens administered for a fixed duration of time may improve outcomes.
Read Article
Polatuzumab Vedotin + Obinutuzumab + Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma
ASH 2019 Wrap-up
Conference Correspondent
Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma.
Read Article
Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with del(17p): Initial Results from Arm C of the SEQUOIA (BGB-3111-304) Trial
ASH 2019 Wrap-up
Conference Correspondent
Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read Article
The iR² Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ASH 2019 Wrap-up
Conference Correspondent
Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant.
Read Article
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Health Policy, In the News
Web Exclusives
The Centers for Medicare & Medicaid Services (CMS) has broadened access to Medicare telehealth services so that beneficiaries can receive a wider range of services from their physicians without having to travel to a healthcare facility. Clinicians can bill immediately for services starting March 6, 2020.
Read Article
Effective Targeted Therapies in CCA: IDH1 and FGFR
Effective Targeted Therapies in CCA: IDH1 and FGFR
By Milind M. Javle, MD; Angela Lamarca, MD, PhD, MSc; Vaibhav Sahai, MBBS, MS
Interview with the Innovators, Cholangiocarcinoma
Videos
Dr Angela Lamarca reviews the current clinical trials with FGFR inhibitors, particularly those with patients with FGFR2 fusion and other genetic aberrations. Dr Vaibhav Sahai highlights those FGFR inhibitors that are nonselective and those that are selective for FGFR1-4, and discusses the clinical trial results with the selective inhibitors, including pemigatinib and infigratinib. He remarks that the response rates and progression-free survival in these trials have been remarkable, far better than what is seen with chemotherapy.
Read Article
Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma
By Phoebe Starr
Hematologic Malignancies, Multiple Myeloma, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—The investigational B-cell maturation antigen (BCMA)-­directed chimeric antigen receptor (CAR) T-cell therapy known as JNJ-4528 induced responses in 100% of 29 evaluable patients with heavily pretreated relapsed or refractory multiple myeloma, according to the results of the phase 1b/2 CARTITUDE-1 clinical trial reported at ASH 2019.
Read Article
Investigational Oral Form of Azacitidine Improves Survival as Maintenance Therapy in Patients with Acute Myeloid Leukemia
By Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—An investigational oral form of azacitidine (CC-486) as maintenance therapy induced a statistically significant improvement in overall survival (OS) compared with placebo in patients with newly diagnosed acute myeloid leukemia (AML) who achieved a complete response or complete response with incomplete hematologic recovery after treatment with induction chemotherapy.
Read Article
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
By Wayne Kuznar
Leukemia, Personalized Medicine
February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights
Orlando, FL—Almost 50% of patients with chronic lymphocytic leukemia (CLL) who received treatment with the triplet of acalabrutinib (Calquence), venetoclax (Venclexta), and obinu­tuzumab (Gazyva) as first-line therapy achieved undetectable minimal residual disease (MRD) in the bone marrow after only 8 monthly cycles of therapy, according to data presented at ASH 2019.
Read Article

Page 79 of 330

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
Amplity
© Amplity, Inc. All Rights Reserved. Privacy Policy.